Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.
about
How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke careMotor System Reorganization After Stroke: Stimulating and Training Toward PerfectionIntravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom OnsetPalliative Care: A Core Competency for Stroke NeurologistsReperfusion therapy of acute ischaemic stroke and acute myocardial infarction: similarities and differencesReview, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptomsOxidative Stress and the Use of Antioxidants in StrokeFeasibility of prehospital teleconsultation in acute stroke--a pilot study in clinical routine.Heart disease and stroke statistics--2014 update: a report from the American Heart AssociationCreating a Novel Video Vignette Stroke Preparedness Outcome Measure Using a Community-Based Participatory Approach.Differences Between US and UK Adults in Stroke Preparedness: Evidence From Parallel Population-Based Community Surveys.Individual and community determinants of calling 911 for stroke among African Americans in an urban community.Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart AssociationBeyond the time window of intravenous thrombolysis: standing by or by stenting?The challenges of implementing a telestroke network: a systematic review and case studyThe future of stroke thrombolysis.Who does it first? The uptake of medical innovations in the performance of thrombolysis on ischemic stroke patients in Germany: a study based on hospital quality data.Magnetic resonance imaging of blood-brain barrier permeability in ischemic stroke using diffusion-weighted arterial spin labeling in rats.Recent advances in the management of acute ischemic stroke.Mechanical thrombectomy in acute stroke: utilization variances and impact of procedural volume on inpatient mortality.Patient Selection for Drip and Ship Thrombolysis in Acute Ischemic StrokeInfluence of hospital-level practices on readmission after ischemic stroke.Intravenous fibrinolysis eligibility: a survey of stroke clinicians' practice patterns and review of the literature.The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.Intravenous thrombolysis in acute ischemic stroke patients with negative CT perfusion: a case series.NeuroThera® Efficacy and Safety Trial-3 (NEST-3): a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera® Laser System for the treatThe quality of treatment of hyperacute ischemic stroke in Canada: a retrospective chart audit.Thrombolysis in acute ischemic stroke: a simulation study to improve pre- and in-hospital delays in community hospitals.Inhibition of retinoblastoma mRNA degradation through Poly (A) involved in the neuroprotective effect of berberine against cerebral ischemiaReducing door-to-puncture times for intra-arterial stroke therapy: a pilot quality improvement projectGlibenclamide for the treatment of ischemic and hemorrhagic stroke.CpG preconditioning regulates miRNA expression that modulates genomic reprogramming associated with neuroprotection against ischemic injury.Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.A Novel Computerized Clinical Decision Support System for Treating Thrombolysis in Patients with Acute Ischemic Stroke.Organization of a United States county system for comprehensive acute stroke care.Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program.Collaterals: Implications in cerebral ischemic diseases and therapeutic interventionsEffects of Xiaoshuan enteric-coated capsule on neurovascular functions assessed by quantitative multiparametric MRI in a rat model of permanent cerebral ischemiaTemporal trends in acute stroke management.
P2860
Q26750590-7BC5620A-84E0-42F6-B509-40938AF00A43Q26795480-1F635156-69A5-49D9-9540-7D1B87540A62Q26796477-69CCAA86-77AB-4412-A370-C72B948CB982Q26799057-FBFDE026-ED6C-4EA0-AC97-BBA656D35195Q26824552-34F51BCA-3E10-448B-A1D8-57BF7B4B19C6Q26825583-D6A0F924-8994-4685-990B-7CD16ABF3016Q26852796-8609A91F-81DF-4C0E-9E00-2F689814A128Q28729871-1D09F950-2728-4186-BEF4-49DD1A9239CBQ29547691-B02422F0-F29E-4BCC-9772-03F6C2071ECDQ30151195-5C10F33A-4C23-46F9-B5C0-22C5298E58F4Q30202552-422624C1-6B55-4821-A732-B3A9EE133AE7Q30223000-F9F02522-C7D0-4131-8D38-044CB427C254Q30238784-85FC43F5-A957-4CC8-970C-0926C51B991DQ30431536-1493BCAC-F883-451F-9722-FBC36BF08441Q30557465-3CE47465-7781-44D2-8E6F-E15BA5448ACFQ30568967-3D9B5CCA-FF09-431A-8ABA-7AA9E419F079Q30884217-50ECF9D8-92C6-4D49-A650-AE69D3A93329Q31136759-328A9B4F-87E9-47D8-B8F6-D17683DEFF62Q33589294-5AE8E831-B21E-48CA-8D03-64A3BABC029AQ33860292-AA95BDBF-62E7-4ABF-9AC3-EA74B451A82AQ33924623-D1638638-1DE2-4060-8B9A-2353BA563AADQ33961755-BF180406-78D8-4802-890C-EDDC59B3BFABQ34150539-318D486F-8157-44CA-A655-0D9FA7023FE3Q34237954-A5A7FD97-0108-437C-BF27-197A836D7AE8Q34286079-28892890-B7A5-4FE4-8F2C-09342F592468Q34421759-80B6D0C9-35D2-408E-8EF7-30EEEDA039EBQ34609355-919E9DC1-13AA-47E6-91C5-D1DA0974D5FAQ35048183-379CBC9F-7181-4719-94C5-7B7D523D9ECAQ35113351-96D37677-8134-4EF8-BA6C-C17022F7DA7FQ35114843-68A8F3CE-C087-450A-8AB3-D9759ED916F4Q35380697-F36B19FF-2318-4A59-8887-EF0BA3964753Q35591239-09C05E1D-4607-4DE0-A839-60FE9B09912DQ35671209-990EFC1C-6257-43AE-AD2C-67113A51EB4DQ35698499-AD354DDF-7885-423C-A4EA-BF55AE698D45Q35858774-C7736532-B4F8-4AF0-B11F-C8052D4EEA52Q35992243-2E03B209-8A55-47A3-85F0-5140CCAD742AQ35993324-03AB615E-C03A-41DD-A431-F69A6C6D4F2CQ36053227-AC8DF791-3E32-44C9-A71E-5146D8C085FEQ36071562-9F9B1608-D2A6-4F88-A3FA-D3244C2814E3Q36100790-C87C3FED-39DA-4D12-AA78-110988D1312D
P2860
Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Recombinant tissue-type plasmi ...... es over the course of 5 years.
@ast
Recombinant tissue-type plasmi ...... es over the course of 5 years.
@en
type
label
Recombinant tissue-type plasmi ...... es over the course of 5 years.
@ast
Recombinant tissue-type plasmi ...... es over the course of 5 years.
@en
prefLabel
Recombinant tissue-type plasmi ...... es over the course of 5 years.
@ast
Recombinant tissue-type plasmi ...... es over the course of 5 years.
@en
P2093
P2860
P1433
P1476
Recombinant tissue-type plasmi ...... es over the course of 5 years.
@en
P2093
Dawn Kleindorfer
Opeolu Adeoye
Pooja Khatri
Richard Hornung
P2860
P304
P356
10.1161/STROKEAHA.110.612358
P407
P577
2011-06-02T00:00:00Z